2021
Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
Kim I, Jang T, Kim S, Lee D, Kim D, Singer E, Ghodoussipour S, Stein M, Aron M, Dall’Era M, Kim I. Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era. Cancer Medicine 2021, 10: 7909-7920. PMID: 34713977, PMCID: PMC8607264, DOI: 10.1002/cam4.4074.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerMetastatic prostate cancer patientsProstate cancer patientsProstate cancerCancer patientsSecond-line antiandrogen therapyProstate cancer-specific survivalCancer-specific survivalNew treatment agentsTherapy eraVisceral metastasesAntiandrogen therapySEER databaseSurvival benefitSurvival outcomesPatientsCancerSurvivalTreatment agentsMenMetastasisTherapyMonthsTranscription factor 4 expression in circulating tumor cells from castration‐resistant prostate cancer
Nagaya N, Lee G, Lu Y, Ashizawa T, Nagata M, Kim I, Horie S. Transcription factor 4 expression in circulating tumor cells from castration‐resistant prostate cancer. IJU Case Reports 2021, 4: 159-162. PMID: 33977248, PMCID: PMC8088892, DOI: 10.1002/iju5.12272.Peer-Reviewed Original ResearchCastration-resistant prostate cancerTranscription factor 4Prostate cancerTumor cellsAntiandrogen therapyNeuroendocrine differentiationFactor 4Group of patientsTranscription factor 4 expressionMessenger ribonucleic acid expressionFactor 4 expressionRibonucleic acid expressionChemotherapy treatmentPatientsDrug resistanceTherapyCancerChemotherapyCellsExpressionPhysicians
2019
Commentary on local therapy in men who present with a metastatic prostate cancer from special issue senior guest editor.
Kim I. Commentary on local therapy in men who present with a metastatic prostate cancer from special issue senior guest editor. American Journal Of Clinical And Experimental Urology 2019, 7: 61-63. PMID: 31139700, PMCID: PMC6526358.Peer-Reviewed Original ResearchReply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today?
Jang T, Kim I, Scardino P, Eastham J. Reply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today? Cancer 2019, 125: 2318-2320. PMID: 30861093, DOI: 10.1002/cncr.32054.Peer-Reviewed Original Research
2016
BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer
Bansal N, Bartucci M, Yusuff S, Davis S, Flaherty K, Huselid E, Patrizii M, Jones D, Cao L, Sydorenko N, Moon Y, Zhong H, Medina D, Kerrigan J, Stein M, Kim I, Davis T, DiPaola R, Bertino J, Sabaawy H. BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer. Clinical Cancer Research 2016, 22: 6176-6191. PMID: 27307599, PMCID: PMC5159329, DOI: 10.1158/1078-0432.ccr-15-3107.Peer-Reviewed Original ResearchConceptsTumor-initiating cellsProstate tumor-initiating cellsBmi-1Androgen receptor-directed therapyIntrinsic therapy resistanceReceptor-directed therapyProstate cancer managementProstate cancer treatmentMore effective therapiesBmi-1 expressionProstate cancer cellsStem cell-like traitsSelf-renewing tumor-initiating cellsCell-like traitsPatient-derived cellsEffective therapyTumor relapseCancer managementXenograft modelTherapy resistancePharmacologic inhibitionBmi-1 functionTherapyNormal tissuesCancer treatmentChapter 3 Androgen Receptor
Modi P, Faiena I, Kim I. Chapter 3 Androgen Receptor. 2016, 21-28. DOI: 10.1016/b978-0-12-800077-9.00003-7.Peer-Reviewed Original ResearchAndrogen receptorProstate cancerAndrogen response elementEndocrine therapyAR signalingCastrate resistanceCell cycle progressionNuclear receptorsTranscriptional regulatory effectsReceptorsVariety of mechanismsRegulatory effectsCell deathPrimary targetCastrationCycle progressionCell growthResponse elementSignificant benefitsTarget genesProtein synthesisPatientsTranscription factorsTherapyProstate
2014
Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review)
FAIENA I, SINGER E, PUMILL C, KIM I. Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review). International Journal Of Oncology 2014, 45: 2193-2198. PMID: 25340386, PMCID: PMC4215584, DOI: 10.3892/ijo.2014.2656.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerProstate cancerMetastatic diseaseSystemic therapyRadical prostatectomyPotential oncologic benefitsDefinitive local therapyPrior radical prostatectomyLow-stage cancersNew surgical paradigmOncologic benefitAcceptable morbidityAdvanced diseaseMetastatic settingLocal therapySimilar morbidityCancer deathKidney cancerStage cancerBetter survivalSurgical paradigmPatientsCancerPotential benefitsTherapyMP78-17 FACTORS ASSOCIATED WITH INITIAL THERAPY FOR REGIONALLY ADVANCED PROSTATE CANCER IN THE UNITED STATES
Jang T, Patel N, Shen S, Karellas M, DiPaola R, Moore D, Kim I, Lu-Yao G. MP78-17 FACTORS ASSOCIATED WITH INITIAL THERAPY FOR REGIONALLY ADVANCED PROSTATE CANCER IN THE UNITED STATES. Journal Of Urology 2014, 191: e927. DOI: 10.1016/j.juro.2014.02.2500.Peer-Reviewed Original Research